Q4 Results 2024 LIVE Updates: NTPC, Hindalco Industries, Ashok Leyland, Glenmark Pharma, Coffee Day Enterprises, more to announce earnings today – Industry News

The company board recommended a final dividend of Re 1 per equity share i.e. 100 per cent of face value of Re 1.00 per equity share for the financial year ended on March 31, 2024. “Approved and fixed Friday, June 14, 2024 as record date for determining the entitlement of the equity shareholders for the purpose of payment of the final dividend for the financial year ended on March 31, 2024,” the company said in a regulatory filing.

Bikaji Foods International reported a profit of Rs 116.28 crore during the fourth quarter of FY24, recording a jump of 200.6 per cent on-year in comparison to Rs 38.68 crore during the same period last year. It posted revenue from operations at Rs 614.45 crore, up 32.9 per cent as against Rs 462.26 crore during the fourth quarter of FY23. The company EBITDA stood at Rs 67.5 crore, up 10.2 per cent on-year.

ICRA Ltd reported a profit of Rs 47.06 crore during the fourth quarter of FY24, up 21.8 per cent in comparison to Rs 38.63 crore recorded during the corresponding quarter of FY23. It posted revenue from operations at Rs 123.96 crore, up 13.6 per cent as against Rs 109.08 crore during the same period of previous financial year. The company EBITDA stood at Rs 49.9 crore, up 31.3 per cent on-year.

The company also recommended a dividend of Rs 100 per equity share of the face value of Rs 10 each.

“We cut our FY25/FY26 EPS estimates by 5/4.1% given: 1) tepid demand environment, more so in 1Q (lack of marriage days); 2) longer than expected time to liquidate old inventory, launch new range/stores and slower ramp up in FILA; and 3) BIS issues affecting high-end international imports. MBL continued to sustain operating parameters with: 1) addition of 19 new cities in FY24 (1 in Q4); 2) increase in online/ Omni channel salience to ~10% of sales without aggressive discounting; and 3) ~50% of sales with MRP >Rs3000 in Q4.

We expect ~210 net store additions including FILA and 5.4% sales/store CAGR over FY24-FY26, We estimate Sales/EBITDA/PAT CAGR of 18.2/18.86%8.41% for FY24-26E.”

– Amnish Aggarwal, Head of Institutional Research, Prabhudas Lilladher Pvt Ltd

Max Healthcare Institute reported EBITDA of Rs 4.94bn (up 15% YoY) which was in-line with our estimates, aided by higher ARPOB at Rs. 78.1k/day; up 11% YoY. The company showed phenomenal growth over FY22-24, despite negligible capacity additions.

“We expect pick-up in the growth momentum given 1) strong expansion plans (+3000 additional beds over FY24-27E), 2) improving payor mix and 3) Bolt on acquisitions like recently added unit in Lucknow and Nagpur. Operational efficiency has also been commendable, especially in competitive markets like NCR. Our FY25E/26E EBITDA broadly remains unchanged however PAT stands reduced by ~5% factoring in recent acquisitions and we expect EBITDA/PAT to grow ~2x over FY24-27E.”

– Param Desai, Senior Research Analyst, Prabhudas Lilladher Pvt Ltd

Fortis Healthcare recorded a profit of Rs 203.14 crore during the fourth quarter of FY24, up 46.9 per cent in comparison to Rs 138.30 crore during the corresponding quarter of previous financial year. It posted revenue from operations at Rs 1785.88 crore, up 8.7 per cent on-year as against Rs 1642.70 crore during the same period last year.

The company board also recommended a final dividend of Re 1 per equity share (10 per cent of face value of Rs 10 each), for the financial year 2023-24, subject to approval of the members of the company.